Cellectar Biosciences Inc (CLRB)
3.33
-0.03
(-0.89%)
USD |
NASDAQ |
May 16, 16:00
3.33
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences Research and Development Expense (Quarterly): 7.378M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.378M |
| December 31, 2023 | 7.936M |
| September 30, 2023 | 7.312M |
| June 30, 2023 | 6.308M |
| March 31, 2023 | 6.654M |
| December 31, 2022 | 5.454M |
| September 30, 2022 | 5.380M |
| June 30, 2022 | 4.499M |
| March 31, 2022 | 3.887M |
| December 31, 2021 | 4.388M |
| September 30, 2021 | 3.938M |
| June 30, 2021 | 4.628M |
| March 31, 2021 | 4.633M |
| December 31, 2020 | 2.375M |
| September 30, 2020 | 2.684M |
| June 30, 2020 | 2.465M |
| March 31, 2020 | 2.616M |
| December 31, 2019 | 2.174M |
| September 30, 2019 | 2.704M |
| June 30, 2019 | 1.810M |
| March 31, 2019 | 2.308M |
| December 31, 2018 | 1.037M |
| September 30, 2018 | 1.996M |
| June 30, 2018 | 1.723M |
| March 31, 2018 | 2.124M |
| Date | Value |
|---|---|
| December 31, 2017 | 3.100M |
| September 30, 2017 | 2.333M |
| June 30, 2017 | 2.176M |
| March 31, 2017 | 1.857M |
| December 31, 2016 | 1.440M |
| September 30, 2016 | 1.306M |
| June 30, 2016 | 0.9652M |
| March 31, 2016 | 1.040M |
| December 31, 2015 | 0.9641M |
| September 30, 2015 | 1.168M |
| June 30, 2015 | 1.383M |
| March 31, 2015 | 1.644M |
| December 31, 2014 | 1.398M |
| September 30, 2014 | 1.470M |
| June 30, 2014 | 1.381M |
| March 31, 2014 | 1.715M |
| December 31, 2013 | 1.554M |
| September 30, 2013 | 2.067M |
| June 30, 2013 | 1.649M |
| March 31, 2013 | 1.591M |
| December 31, 2012 | 1.227M |
| September 30, 2012 | 1.253M |
| June 30, 2012 | 1.315M |
| March 31, 2012 | 1.328M |
| December 31, 2011 | 1.154M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.810M
Minimum
Jun 2019
7.936M
Maximum
Dec 2023
4.461M
Average
4.443M
Median
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.08M |
| Eli Lilly and Co | 2.523B |
| Actinium Pharmaceuticals Inc | 6.635M |
| Bristol-Myers Squibb Co | 2.695B |
| Altimmune Inc | 21.49M |